Free Trial
NASDAQ:ZNTL

Zentalis Pharmaceuticals Q4 2024 Earnings Report

Zentalis Pharmaceuticals logo
$1.43 -0.08 (-5.30%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$1.43 0.00 (0.00%)
As of 04/25/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zentalis Pharmaceuticals EPS Results

Actual EPS
-$0.66
Consensus EPS
-$0.75
Beat/Miss
Beat by +$0.09
One Year Ago EPS
N/A

Zentalis Pharmaceuticals Revenue Results

Actual Revenue
$26.90 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zentalis Pharmaceuticals Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 26, 2025
Conference Call Time
11:30AM ET

Upcoming Earnings

Zentalis Pharmaceuticals' next earnings date is estimated for Tuesday, May 6, 2025, based on past reporting schedules.

Zentalis Pharmaceuticals Earnings Headlines

$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
See More Zentalis Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zentalis Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zentalis Pharmaceuticals and other key companies, straight to your email.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

View Zentalis Pharmaceuticals Profile

More Earnings Resources from MarketBeat